Role of the UGT2B17 deletion in exemestane pharmacogenetics

Exemestane (EXE) is an aromatase inhibitor used for the prevention and treatment of breast cancer. The major metabolic pathway for EXE is reduction to form the active 17β-dihydro-EXE (17β-DHE) and subsequent glucuronidation to 17β-hydroxy-EXE-17-O-β-D-glucuronide (17β-DHE-Gluc) by UGT2B17. The aim o...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Shaman, Chen, Gang, Truica, Cristina, Baird, Cynthia C., Leitzel, Kim, Lazarus, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700874/
https://www.ncbi.nlm.nih.gov/pubmed/28534527
http://dx.doi.org/10.1038/tpj.2017.18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700874/
https://www.ncbi.nlm.nih.gov/pubmed/28534527
http://dx.doi.org/10.1038/tpj.2017.18

Ejemplares similares